Skip to main content
. Author manuscript; available in PMC: 2018 Jun 12.
Published in final edited form as: Virology. 2016 Aug 10;497:314–322. doi: 10.1016/j.virol.2016.08.002

Table 6.

Associations between condyloma and beta (β)-HPV DNA detected on the surface of condyloma cases and the normal genital skin of condyloma cases and controls, at the time of lesion detection (index visit), 6, and 12 months prior to lesion detection

HPV species/type Condyloma/Suggestive of Condyloma
n=43
Normal genital skin Condyloma/Suggestive of Condyloma
12mo prior 6mo prior Index visit Index visit
ORa aOR (95% CI)b ORa aOR (95% CI)b ORa aOR (95% CI)b ORa aOR (95% CI)c
Any β-HPV type 1.11 0.98 (0.20–5.13) 0.75 0.85 (0.19–4.09) 0.62 0.49 (0.11–2.03) 0.37 0.62 (0.12–3.09)
 β1
  Any β1 1.32 1.19 (0.43–3.46) 1.05 0.79 (0.28–2.26) 1.14 0.97 (0.28–3.46) 0.60 0.55 (0.13–2.12)
  HPV5 1.44 0.99 (0.30–3.05) 1.33 0.82 (0.24–2.54) 1.14 1.12 (0.35–3.39) 0.53 0.86 (0.12–5.67)
  HPV8 0.62 0.50 (0.07–2.53) 0.75 0.42 (0.07–1.82) 1.52 0.83 (0.17–3.60) 0.82 2.64 (0.36–21.26)
  HPV12 1.97 1.66 (0.43–6.47) 1.89 2.99 (0.70–15.2) 1.88 2.52 (0.48–15.59) 0.48 0.42 (0.02–5.76)
  HPV14 1.67 1.78 (0.32–9.53) 4.22 2.17 (0.34–15.53) 4.22 1.74 (0.22–14.95) 4.22 3.55 (0.42–42.89)
  HPV19 NE NE 2.00 NE NE NE NE NE
  HPV20 NE NE NE NE 1.50 0.78 (0.04–15.49) 1.00 1.31 (0.04–30.14)
  HPV21 4.00 4.77 (0.58–63.93) 2.00 1.11 (0.15–6.77) 0.44 0.08 (0–1.27) 0.40 1.12 (0.09–9.47)
  HPV24 0.41 0.42 (0.06–1.91) 1.08 1.01 (0.24–3.89) 0.84 0.88 (0.19–3.55) 0.09 0.05 (0.01–0.77)
  HPV25 NE NE NE NE 2.00 2.00 (0–38.00) NE NE
  HPV36 0.62 0.93 (0.18–3.78) 1.12 0.75 (0.11–3.71) 1.36 0.81 (0.17–3.29) 0.67 0.30 (0.02–2.92)
  HPV47 0.25 0.09 (0–0.73) 0.32 0.24 (0.04–1.00) 1.66 1.17 (0.35–3.73) 0.20 0.57 (0.04–4.59)
  HPV93 NE NE 2.00 2.00 (0.11–NE) 2.00 11.39 (0–216.45) NE NE
 β2
  Any β2 1.79 2.22 (0.78–7.09) 1.77 1.46 (0.58–3.97) 0.83 0.72 (0.26–1.94) 0.51 1.28 (0.36–5.15)
  HPV9 0.44 0.24 (0.01–1.94) 0.17 0.24 (0.01–1.86) 1.60 1.13 (0.13–9.79) 0.67 0.39 (0.01–14.07)
  HPV15 1.25 1.21 (0.21–5.85) 1.94 1.83 (0.40–8.61) 2.91 4.74 (0.61–60.35) 0.80 0.39 (0.01–13.87)
  HPV17 1.43 1.60 (0.33–7.58) 2.29 1.30 (0.34–4.85) 1.57 1.17 (0.27–4.63) 0.81 1.77 (0.19–16.12)
  HPV22 1.41 1.82 (0.50–6.97) 2.21 1.87 (0.62–5.84) 1.24 1.11 (0.31–3.87) 0.28 0.58 (0.07–3.42)
  HPV23 1.94 2.99 (0.84–12.22) 1.49 1.70 (0.48–5.97) 1.17 1.00 (0.22–3.90) 0.55 0.79 (0.07–7.03)
  HPV37 0.84 0.93 (0.13–5.13) 0.16 0.15 (0–2.24) 0.25 0.51 (0–3.04) 0.15 2.97 (0–26.27)
  HPV38 1.66 1.84 (0.57–6.12) 2.44 2.03 (0.74–5.93) 0.73 0.78 (0.20–2.76) 0.71 1.59 (0.31–8.83)
  HPV80 5.33 3.05 (0.50–22.97) 1.57 1.37 (0.36–4.94) NE NE 2.26 2.61 (0.18–39.95)
 β3
  Any β3 1.84 2.23 (0.31–16.42) 5.16 2.92 (0.63–15.83) 2.91 3.92 (0.57–33.84) NE NE
  HPV49 2.00 2.00 (0.14–27.59) 5.00 3.05 (0.23–59.76) 2.00 2.97 (0.19–48.98) NE NE
  HPV75 NE NE 3.33 1.90 (0.18–25.03) NE NE NE NE
  HPV76 1.41 0.37 (0–44.48) NE NE 1.00 0.55 (0–24.84) NE NE
 β4
  HPV92 NE NE 1.33 0.52 (0–29.37) NE NE NE NE
 β5
  HPV96 0.86 0.96 (0.12–5.46) 1.00 0.99 (0.10–7.52) 0.29 0.09 (0–1.36) 0.54 0.66 (0.03–8.50)
Multiple β-HPV types
 ≥2 types 1.41 1.62 (0.59–4.67) 1.32 0.95 (0.37–2.49) 0.90 1.25 (0.43–3.74) 0.45 1.37 (0.33–6.66)

NE: Not estimable

Note: Sample sizes change depending on specimen availability and validity of HPV results.

a

Unadjusted model; bolded OR indicates a statistically significant association (p<0.05).

b

Adjusted for presence of alpha-HPV 6/11 DNA on the normal genital skin of cases and controls at the corresponding visit; surface of normal genital skin and EGL specimens were evaluated for α-HPV using Linear Array.

c

Adjusted for presence of alpha-HPV 6/11 DNA within EGL tissue of cases and normal genital skin of controls at the index visit; EGL tissue biopsies were evaluated for α-HPV using INNO-LiPA and the surface of normal genital skin specimens were evaluated for α-HPV using Linear Array.